UCB S.A.’s plaque psoriasis therapy, bimekizumab, has become the first product to be cleared for use on the National Health Service in England by the health technology appraisal (HTA) body NICE via a new approach to the fast-track cost-comparison review process.
The fast-track appraisal (FTA) procedure was originally introduced in April 2017 for assessing products that offered “exceptional value for money,” for example where a cost comparison showed that they were likely to provide similar or greater benefits at similar or
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?